Quick Answer
Century Therapeutics, Inc. reported Stockholders Equity of $158.94 million for the year ending 2025.
- Century Therapeutics, Inc. showed a decrease of -1.5% in Stockholders Equity from 2024 to 2025.
- This data is from Century Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$101.28 million | Q2 2020: -$116.35 million | Q3 2020: -$129.31 million | Q1 2021: -$91.56 million | Q2 2021: $447.60 million | Q3 2021: $422.99 million | Q1 2022: $386.66 million | Q2 2022: $357.95 million | Q3 2022: $330.21 million | Q1 2023: $277.18 million | Q2 2023: $247.57 million | Q3 2023: $219.23 million | Q1 2024: $177.88 million | Q2 2024: $222.10 million | Q3 2024: $195.69 million | Q1 2025: $240.44 million | Q2 2025: $209.90 million | Q3 2025: $176.35 million.
- Over the full 7 years of available data (2019 to 2025), Century Therapeutics, Inc.'s Stockholders Equity has grown by 273.0%.
- Historical annual values: Fiscal year 2025: $158.94 million | Fiscal year 2024: $161.36 million | Fiscal year 2023: $184.75 million | Fiscal year 2022: $302.74 million | Fiscal year 2021: $396.24 million | Fiscal year 2020: -$106.41 million | Fiscal year 2019: -$91.86 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: